Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of B-hCD19 MC38 Cells Induced Tumor Models (CAT#: STEM-AE-0158-LGZ)

Introduction

The mouse Cd19 gene was replaced by human CD19 coding sequence in B-hCD19 MC38 cells. Human CD19 is highly expressed on the surface of B-hCD19 MC38 cells.<br />B-hCD19 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.<br />Common name: B-hCD19 MC38<br />Aliases: CD19, CD19 molecule, B4, CVID3<br />Organism: Mouse<br />Tissue types: Colon<br />Disease: Colon carcinoma<br />Strain: C57BL/6<br />Tissue: Colon




Principle

Tumor-associated antigen (TAA) refers to antigen molecules that are specific or highly expressed in Tumor cells but absent or underexpressed in healthy cells, and are involved in the proliferation, differentiation, and migration of tumor cells. This makes TAA a potential effective molecular target of antitumor drugs. Taa-targeted drugs can kill tumor cells by mediating ADCC, CDC, and activating immune response. For this type of drug, subcutaneous inoculation of wild-type mice or in situ inoculation of humanized mouse cell lines can be used to evaluate its efficacy. We have developed a series of humanized cell lines for pharmacodynamic evaluation based on the current market demand for TAA target drug development. Some of the TAA targets are expressed in healthy tissues and cells and play important physiological functions. The drugs of these targets may have serious toxic and side effects, so we can provide the corresponding humanized animal models for drug safety evaluation.

Applications

Colon carcinoma

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder
Advertisement